Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

On May 17, 2022, Epizyme, Inc. (the "Company") held its 2022 Annual Meeting of Stockholders ("2022 Annual Meeting") and, among other things, the Company's stockholders approved (i) the Epizyme, Inc. 2022 Equity Incentive Plan as the successor to the Epizyme, Inc. 2013 Stock Incentive Plan and (ii) an amendment to the Epizyme, Inc. 2013 Employee Stock Purchase Plan.

The foregoing descriptions of the 2022 Equity Incentive Plan and the amendment to the 2013 Employee Stock Purchase Plan do not purport to be complete and are qualified in their entirety by reference to the 2022 Equity Incentive Plan (effective as of May 17, 2022) and to the 2013 Employee Stock Purchase Plan (as amended, effective September 1, 2022), attached to this Current Report on Form 8-K as Exhibit 10.1 and Exhibit 10.2, respectively.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its 2022 Annual Meeting on May 17, 2022. The following is a summary of the matters voted on at the 2022 Annual Meeting.



a)  The stockholders of the Company elected Michael F. Giordano, M.D., Pablo
    Legorreta, David M. Mott, and Carol Stuckley as Class III directors, each for
    a three-year term ending at the annual meeting of stockholders to be held in
    2025. The results of the stockholders' vote with respect to the election of
    the Class III directors were as follows:



                                                 Votes            Broker
Name                          Votes For         Withheld        Non-Votes
Michael F. Giordano, M.D.     119,824,506          785,156       14,164,976
Pablo Legorreta               117,113,067        3,496,595       14,164,976
David M. Mott                  68,970,172       51,639,490       14,164,976
Carol Stuckley                120,177,308          432,354       14,164,976



b)  The stockholders of the Company ratified the selection of Ernst & Young LLP
    as the Company's independent registered public accounting firm for the fiscal
    year ending December 31, 2022. The results of the stockholders' vote with
    respect to such ratification were as follows:



                                   Broker
    For       Against   Abstain   Non-Votes
134,133,038   257,984   383,616       0



c)  The stockholders of the Company approved the non-binding, advisory proposal
    on the compensation of the Company's named executive officers. The results of
    the stockholders' vote with respect to the non-binding, advisory proposal
    were as follows:



                                    Broker
    For       Against   Abstain   Non-Votes
119,573,086   928,974   107,602   14,164,976



d)  The stockholders of the Company approved an amendment to the Company's
    Restated Certificate of Incorporation to increase the number of authorized
    shares of the Company's common stock from 225,000,000 to 450,000,000. The
    amendment to the Company's Restated Certificate of Incorporation was filed
    with the Secretary of State of the State of Delaware on May 17, 2022. The
    results of the stockholders' vote with respect to the amendment were as
    follows:



                                     Broker
    For        Against    Abstain   Non-Votes
131,459,960   3,287,769   26,909        0



                                       2

--------------------------------------------------------------------------------


e)  The stockholders of the Company approved the Epizyme, Inc. 2022 Equity
    Incentive Plan. The results of the stockholders' vote with respect to the new
    equity incentive plan were as follows:



                                      Broker
    For        Against    Abstain   Non-Votes
117,057,031   3,514,382   38,249    14,164,976



f)  The stockholders of the Company approved an amendment to the Epizyme, Inc.
    2013 Employee Stock Purchase Plan to eliminate the annual "evergreen"
    provision and authorize 2,500,000 shares of the Company's common stock for
    issuance under such plan. The results of the stockholders' vote with respect
    to the amendment were as follows:



                                    Broker
    For       Against   Abstain   Non-Votes
120,118,485   473,486   17,691    14,164,976

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



10.1      Epizyme, Inc. 2022 Equity Incentive Plan

10.2      Epizyme, Inc. 2013 Employee Stock Purchase Plan, as amended and
        effective September 1, 2022

104     Cover Page Interactive Data File (embedded within XBRL document)



                                       3

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses